Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med. 2015 Oct 22;373(17):1672-1673
To the Editor: In the PALOMA3 study, Turner et al. (July 16 issue)(1) report that the addition of palbociclib to fulvestrant improved progression-free survival as compared with fulvestrant alone in patients with advanced breast cancer, with similar discontinuation rates because of adverse effects (2.6% and 1.7%, respectively). However, molecularly targeted therapies have moderate toxic effects that may become unacceptable over the long term and result in a deterioration in the quality of life, as shown in a previous report.(2),(3) The PALOMA1 study, a previous phase 2 trial of palbociclib with a median follow-up of approximately 30 months, showed that . . .
PMID: 26488700 [PubMed – as supplied by publisher]